(Reuters) -German science and technology group Merck is open to more acquisitions for its Life Science business after ...

Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The ...

Merck KGaA said it’s seeing the beginning of a post-Covid pandemic rebound in life sciences as it reaffirmed the group’s sales and profit guidance for the full year. The German science and ...

Merck KGaA’sMRK-1.94%decrease ... sales grow faster than previously expected over the medium term. The life-sciences and chemicals group lifted its mid-term outlook for its electronics business ...

Merck MRK-1.63%decrease; red down pointing triangle KGaA lowered its medium-term outlook for its healthcare and life-science segment due to China challenges and recent pipeline setbacks but raised ...

Based outside Boston, MilliporeSigma was formed after Merck KGaA acquired St. Louis-based Sigma-Aldrich Corp. for $17 billion ...

MilliporeSigma has about 1,700 employees in Wisconsin at facilities in Milwaukee, Port Washington, Sheboygan and in the ...

German science and technology giant Merck on Thursday said it is confident of returning to medium-term growth after a significant drop in profits in 2023. At an investment day at its headquarters ...

Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...

targeting larger deals in the life-sciences business to build on its $600 million deal for U.S. company Mirus Bio in July. In healthcare, Merck will seek to intensify licensing of drug candidates ...

GERMAN science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for US$600 million, it said ahead of its Capital ...